MBX Biosciences (MBX) Competitors $12.95 +0.42 (+3.35%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$13.27 +0.32 (+2.50%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. BHVN, AUPH, JANX, DYN, TVTX, SDGR, EWTX, ANIP, WVE, and ETNBShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Biohaven (BHVN), Aurinia Pharmaceuticals (AUPH), Janux Therapeutics (JANX), Dyne Therapeutics (DYN), Travere Therapeutics (TVTX), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), ANI Pharmaceuticals (ANIP), WAVE Life Sciences (WVE), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Its Competitors Biohaven Aurinia Pharmaceuticals Janux Therapeutics Dyne Therapeutics Travere Therapeutics Schrodinger Edgewise Therapeutics ANI Pharmaceuticals WAVE Life Sciences 89BIO Biohaven (NYSE:BHVN) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Which has stronger valuation and earnings, BHVN or MBX? MBX Biosciences is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiohavenN/AN/A-$846.42M-$7.66-1.88MBX BiosciencesN/AN/AN/A-$4.54-2.85 Does the media favor BHVN or MBX? In the previous week, Biohaven had 36 more articles in the media than MBX Biosciences. MarketBeat recorded 41 mentions for Biohaven and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.42 beat Biohaven's score of 0.02 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 2 Very Positive mention(s) 4 Positive mention(s) 22 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of BHVN or MBX? 88.8% of Biohaven shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 52.2% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is BHVN or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets BiohavenN/A -270.65% -143.70% MBX Biosciences N/A N/A N/A Do analysts prefer BHVN or MBX? Biohaven currently has a consensus price target of $53.75, indicating a potential upside of 273.00%. MBX Biosciences has a consensus price target of $37.63, indicating a potential upside of 190.54%. Given Biohaven's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biohaven is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biohaven 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.07MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBiohaven beats MBX Biosciences on 7 of the 12 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$435.04M$816.05M$5.54B$20.86BDividend YieldN/A4.84%4.62%3.60%P/E Ratio-2.851.2030.1528.45Price / SalesN/A36.57461.3481.64Price / CashN/A19.5637.7523.46Price / BookN/A6.588.495.45Net IncomeN/A-$4.11M$3.26B$994.60M7 Day Performance16.35%4.20%4.19%3.03%1 Month Performance-6.63%-0.32%4.64%1.91%1 Year PerformanceN/A20.22%35.15%16.34% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.554 of 5 stars$12.95+3.4%$37.63+190.5%N/A$435.04MN/A-2.8536News CoverageBHVNBiohaven3.2213 of 5 stars$15.11+2.7%$58.46+286.9%-63.3%$1.54BN/A-1.62239Trending NewsEarnings ReportAnalyst ForecastAUPHAurinia Pharmaceuticals2.2242 of 5 stars$11.65+1.7%$12.00+3.0%+120.4%$1.53B$235.13M27.12300Positive NewsJANXJanux Therapeutics2.0073 of 5 stars$25.77+7.8%$91.89+256.5%-34.5%$1.53B$9.34M-18.9530Earnings ReportAnalyst RevisionDYNDyne Therapeutics3.5752 of 5 stars$10.61+3.5%$36.25+241.8%-72.0%$1.51BN/A-2.75100TVTXTravere Therapeutics2.0663 of 5 stars$16.60+4.0%$32.14+93.6%+104.2%$1.47B$233.18M-5.91460Analyst RevisionSDGRSchrodinger3.0256 of 5 stars$19.76-1.2%$32.75+65.8%-0.4%$1.45B$207.54M-7.51790Analyst RevisionEWTXEdgewise Therapeutics1.9582 of 5 stars$13.610.0%$40.55+198.0%-19.7%$1.43BN/A-8.7860Earnings ReportAnalyst RevisionANIPANI Pharmaceuticals3.2686 of 5 stars$65.65+0.3%$78.88+20.2%+50.5%$1.42B$674.07M-51.68600Earnings ReportAnalyst ForecastWVEWAVE Life Sciences4.7722 of 5 stars$8.79+0.5%$20.27+130.6%+57.3%$1.40B$108.30M-9.77240ETNB89BIO2.1541 of 5 stars$9.52+1.9%$26.43+177.6%+14.0%$1.39BN/A-2.8240Earnings ReportAnalyst Revision Related Companies and Tools Related Companies Biohaven Competitors Aurinia Pharmaceuticals Competitors Janux Therapeutics Competitors Dyne Therapeutics Competitors Travere Therapeutics Competitors Schrodinger Competitors Edgewise Therapeutics Competitors ANI Pharmaceuticals Competitors WAVE Life Sciences Competitors 89BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access